Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Study Identifier:
ACH471-100
ClinicalTrials.gov Identifier:
EudraCT Identifier:
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Danicopan
Date
Mar 2017 - Nov 2018
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years
Requirements Information
Sex
Female & Male
Age
18+ years
Study Details
Medical Condition
- Unmapped
Study Drug
- Drug: Danicopan
Date
Mar 2017 - Nov 2018
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18+ years years
Requirements Information
Protocol Summary
The purpose of this study was to determine the safety and efficacy of ACH-0144471 (also known as danicopan and ALXN2040) in currently untreated participants with PNH.
Trial Locations
Location
Status
Location
Clinical Trial Site
Florence, Italy
Status
N/A
Location
Clinical Trial Site
Naples, Italy
Status
N/A
Location
Clinical Trial Site
Seoul, Republic of Korea
Status
N/A
Location
Clinical Trial Site
Auckland, New Zealand
Status
N/A
Location
Clinical Trial Site
London, United Kingdom
Status
N/A